<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Sauty A</dc:creator>
  <dc:creator>Rochat T</dc:creator>
  <dc:creator>Schoch OD</dc:creator>
  <dc:creator>Hamacher J</dc:creator>
  <dc:creator>Kurt AM</dc:creator>
  <dc:creator>Dayer JM</dc:creator>
  <dc:creator>Nicod LP</dc:creator>
  <dc:date>1997</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Interstitial lung disease (ILD) is a complication of polymyositis (PM) and dermatomyositis (DM). It often manifests itself in association with myositis-specific antisynthetase autoantibodies, among which anti-Jo-1 antibodies are the most commonly encountered. In contrast, ILD associated with anti-Jo-1 antibodies without muscle involvement is rare and not well characterized. We report four patients presenting with ILD associated with anti-Jo-1 antibodies. Histological findings of transbronchial biopsies disclosed a pattern consistent with nonspecific interstitial pneumonitis, a CD8+ lymphocytosis was found in bronchoalveolar lavage. Only one of these patients developed an "antisynthetase syndrome" with PM, after nearly 2 yrs of severe ILD. The clinical conditions of all four cases showed stabilization or improvement when cyclosporine was added to their immunosuppressive treatment. These cases confirm that a CD8+ lymphocytic interstitial lung disease may be the first, and sole manifestation of autoimmune disease associated with anti-Jo-1 antibodies. Furthermore, they suggest that this form of interstitial lung disease apparently has a poor response to steroids and cytotoxic drugs, but may respond to moderate doses of cyclosporine and azathioprine in addition to low doses of steroids.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/127544</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1183/09031936.97.10122907</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9493684</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>The European respiratory journal. - 1997</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Antibodies, Antinuclear</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Autoantibodies</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Azathioprine</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Biopsy, Needle</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Bronchoalveolar Lavage Fluid</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">CD8-Positive T-Lymphocytes</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Cyclosporins</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Drug Therapy, Combination</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Immunosuppressive Agents</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Lung Diseases, Interstitial</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Lymphocyte Count</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Pulmonary Fibrosis</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Steroids</dc:subject>
  <dc:title xmlns:ns19="xml" ns19:lang="en">Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>